Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 4
2005 4
2006 9
2007 2
2008 6
2009 3
2010 7
2011 7
2012 5
2013 3
2014 2
2015 3
2016 6
2017 6
2018 13
2019 11
2020 16
2021 28
2022 16
2023 12
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for wei wen su
Search for Wei-Wen Fu instead (1 results)
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs.
Chen X, Li A, Sun BF, Yang Y, Han YN, Yuan X, Chen RX, Wei WS, Liu Y, Gao CC, Chen YS, Zhang M, Ma XD, Liu ZW, Luo JH, Lyu C, Wang HL, Ma J, Zhao YL, Zhou FJ, Huang Y, Xie D, Yang YG. Chen X, et al. Among authors: wei ws. Nat Cell Biol. 2019 Aug;21(8):978-990. doi: 10.1038/s41556-019-0361-y. Epub 2019 Jul 29. Nat Cell Biol. 2019. PMID: 31358969
m5C-dependent cross-regulation between nuclear reader ALYREF and writer NSUN2 promotes urothelial bladder cancer malignancy through facilitating RABL6/TK1 mRNAs splicing and stabilization.
Wang N, Chen RX, Deng MH, Wei WS, Zhou ZH, Ning K, Li YH, Li XD, Ye YL, Wen JH, Dong B, Zhang XP, Liu ZW, Zhou FJ. Wang N, et al. Among authors: wei ws. Cell Death Dis. 2023 Feb 18;14(2):139. doi: 10.1038/s41419-023-05661-y. Cell Death Dis. 2023. PMID: 36806253 Free PMC article.
Single-cell transcriptomics reveals a low CD8+ T cell infiltrating state mediated by fibroblasts in recurrent renal cell carcinoma.
Peng YL, Xiong LB, Zhou ZH, Ning K, Li Z, Wu ZS, Deng MH, Wei WS, Wang N, Zou XP, He ZS, Huang JW, Luo JH, Liu JY, Jia N, Cao Y, Han H, Guo SJ, Dong P, Yu CP, Zhou FJ, Zhang ZL. Peng YL, et al. Among authors: wei ws. J Immunother Cancer. 2022 Feb;10(2):e004206. doi: 10.1136/jitc-2021-004206. J Immunother Cancer. 2022. PMID: 35121646 Free PMC article.
Non-viral 2A-like sequences for protein coexpression.
Su WW, Zhang B, Han Z, Kumar S, Gupta M. Su WW, et al. J Biotechnol. 2022 Nov 10;358:1-8. doi: 10.1016/j.jbiotec.2022.08.014. Epub 2022 Aug 20. J Biotechnol. 2022. PMID: 35995093
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry.
Chang TS, Huang CF, Kuo HT, Lo CC, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Chen CY, Tseng KC, Hung CH, Yu ML. Chang TS, et al. Among authors: su ww. Hepatol Int. 2023 Jun;17(3):550-561. doi: 10.1007/s12072-023-10506-z. Epub 2023 Mar 27. Hepatol Int. 2023. PMID: 36973633 Free PMC article.
Visual Subfield Progression in Glaucoma Subtypes.
Su WW, Hsieh SS, Cheng ST, Su CW, Wu WC, Chen HS. Su WW, et al. J Ophthalmol. 2018 Mar 21;2018:7864219. doi: 10.1155/2018/7864219. eCollection 2018. J Ophthalmol. 2018. PMID: 29750123 Free PMC article.
156 results